K Sivanesam1, A Byrne1, M Bisaglia2, L Bubacco2, N Andersen1. 1. Department of Chemistry, University of Washington, Seattle, WA 98195. 2. Department of Biology, University of Padua, 35121 Padova, Italy.
Abstract
Further examination of peptides with well-folded antiparallel β strands as inhibitors of amyloid formation from α-synuclein has resulted in more potent inhibitors. Several of these had multiple Tyr residues and represent a new lead for inhibitor design by small peptides that do not divert α-synuclein to non-amyloid aggregate formation. The most potent inhibitor obtained in this study is a backbone cyclized version of a previously studied β hairpin, designated as WW2, with a cross-strand Trp/Trp cluster. The cyclization was accomplished by adding a d-Pro-l-Pro turn locus across strand termini. At a 2:1 peptide to α-synuclein ratio, cyclo-WW2 displays complete inhibition of β-structure formation. Trp-bearing antiparallel β-sheets held together by a disulphide bond are also potent inhibitors. 15N HSQC spectra of α-synuclein provided new mechanistic details. The time course of 15N HSQC spectral changes observed during β-oligomer formation has revealed which segments of the structure become part of the rigid core of an oligomer at early stages of amyloidogenesis and that the C-terminus remains fully flexible throughout the process. All of the effective peptide inhibitors display binding-associated titration shifts in 15N HSQC spectra of α-synuclein in the C-terminal Q109-E137 segment. Cyclo-WW2, the most potent inhibitor, also displays titration shifts in the G41-T54 span of α-synuclein, an additional binding site. The earliest aggregation event appears to be centered about H50 which is also a binding site for our most potent inhibitor.
Further examination of peptides with well-folded antiparallel β strands as inhibitors of amyloid formation from α-synuclein has resulted in more potent inhibitors. Several of these had multiple n class="Chemical">Tyr residues and represent a new lead for inhibitor design by small peptides that do not divert α-synuclein to non-amyloid aggregate formation. The most potent inhibitor obtained in this study is a backbone cyclized version of a previously studied β hairpin, designated as WW2, with a cross-strand Trp/Trp cluster. The cyclization was accomplished by adding a d-Pro-l-Pro turn locus across strand termini. At a 2:1 peptide to α-synuclein ratio, cyclo-WW2 displays complete inhibition of β-structure formation. Trp-bearing antiparallel β-sheets held together by a disulphide bond are also potent inhibitors. 15N HSQC spectra of α-synuclein provided new mechanistic details. The time course of 15N HSQC spectral changes observed during β-oligomer formation has revealed which segments of the structure become part of the rigid core of an oligomer at early stages of amyloidogenesis and that the C-terminus remains fully flexible throughout the process. All of the effective peptide inhibitors display binding-associated titration shifts in 15N HSQC spectra of α-synuclein in the C-terminal Q109-E137 segment. Cyclo-WW2, the most potent inhibitor, also displays titration shifts in the G41-T54 span of α-synuclein, an additional binding site. The earliest aggregation event appears to be centered about H50 which is also a binding site for our most potent inhibitor.
Authors: K Uéda; H Fukushima; E Masliah; Y Xia; A Iwai; M Yoshimoto; D A Otero; J Kondo; Y Ihara; T Saitoh Journal: Proc Natl Acad Sci U S A Date: 1993-12-01 Impact factor: 11.205
Authors: Jordan M Anderson; Brandon L Kier; Brice Jurban; Aimee Byrne; Irene Shu; Lisa A Eidenschink; Alexander A Shcherbakov; Mike Hudson; R M Fesinmeyer; Niels H Andersen Journal: Biopolymers Date: 2016-06 Impact factor: 2.505
Authors: Kalkena Sivanesam; Irene Shu; Kelly N L Huggins; Marianna Tatarek-Nossol; Aphrodite Kapurniotu; Niels H Andersen Journal: FEBS Lett Date: 2016-07-08 Impact factor: 4.124
Authors: Karima Schwab; Silke Frahm; David Horsley; Janet E Rickard; Valeria Melis; Elizabeth A Goatman; Mandy Magbagbeolu; Morag Douglas; Michael G Leith; Thomas C Baddeley; John M D Storey; Gernot Riedel; Claude M Wischik; Charles R Harrington; Franz Theuring Journal: Front Mol Neurosci Date: 2018-01-10 Impact factor: 5.639